睿知中国疾病研究地图
候选清单0

天津天津医科大学

天津医科大学肿瘤医院

Tianjin Medical University Cancer Institute & Hospital

在本站收录的 53 种疾病中,这家医院列在其中 12 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

天津医科大学肿瘤医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma7 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma47 篇牵头论文牵头 12 项开放试验
  3. 肝细胞癌Hepatocellular carcinoma88 篇牵头论文牵头 11 项开放试验
  4. 胃癌Stomach cancer78 篇牵头论文牵头 6 项开放试验
  5. 肝母细胞瘤Hepatoblastoma1 篇牵头论文
  6. 脊索瘤Chordoma1 篇牵头论文
  7. 骨肉瘤Osteosarcoma18 篇牵头论文
  8. 胃肠道间质瘤Gastrointestinal stromal tumour2 篇牵头论文
  9. 神经母细胞瘤Neuroblastoma21 篇牵头论文牵头 1 项开放试验
  10. 尤文肉瘤Ewing sarcoma1 篇牵头论文
  11. 多发性骨髓瘤Multiple myeloma10 篇牵头论文牵头 1 项开放试验
  12. 家族性腺瘤性息肉病Familial adenomatous polyposis1 篇牵头论文

未列出的收录疾病:视网膜母细胞瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.3%。

牵头论文
7
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 3320222023: 1120232024: 1120242025: 112025

天津有 2 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    QL1706(PD-1/CTLA-4 双特异性抗体)联合放化疗用于局部区域晚期鼻咽癌QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    分期
    III期
    开始
    2025-05
    登记号
    NCT06749899

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 17 家列出的医院为研究中心上海、东莞、中山、佛山、南京、南宁、厦门、天津、广州、成都、武汉、福州、贵阳、长沙

  2. 正在招募
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    分期
    III期
    开始
    2024-03
    登记号
    NCT06239727

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 21 家列出的医院为研究中心东莞、佛山、南京、南宁、南昌、厦门、天津、广州、成都、杭州、武汉、汕头、海口、湛江、福州、西安、贵阳、重庆、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。卡片标题如有中文,为 AI 生成的译文,英文原文附后。

这些数字背后的记录
研究主题放疗技术副作用与生活质量影像与人工智能
论文中的科室放疗科肿瘤内科
牵头的论文7
  1. Induction chemotherapy plus camrelizumab combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma in non-endemic areas: a phase 2 clinical trial in North China.2025BMC medicine免费全文
  2. The impact of submandibular glands protection on xerostomia as monitored by diffusion-weighted imaging in nasopharyngeal carcinoma patients.2024Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  3. Development and validation of a nomogram for prediction of recovery from moderate-severe xerostomia post-radiotherapy in nasopharyngeal carcinoma patients.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  4. Traditional Chinese medicine formula 01 for nasopharyngeal carcinoma (NPC01) for head & neck cancer and health-related quality of life: a retrospective study.2022BMC complementary medicine and therapies免费全文
  5. IGF2BP3 promotes cell metastasis and is associated with poor patient survival in nasopharyngeal carcinoma.2022Journal of cellular and molecular medicine免费全文
  6. What is the appropriate skin cleaning method for nasopharyngeal cancer radiotherapy patients? A randomized controlled trial.2022Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerRCT
  7. MicroRNA-203a-3p affects the biological characteristics of nasopharyngeal carcinoma by targeting vascular endothelial growth factor-C.2021Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma状态不明NCT04782765牵头方II期2021-03 启动
  2. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.正在招募NCT06749899研究中心III期2025-05 启动
  3. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response正在招募NCT06239727研究中心III期2024-03 启动
  4. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  5. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer状态不明NCT01074021研究中心III期2009-10 启动
PubMed 以外找到的论文(未计入)8
  1. Abstract CT227: Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study2024Cancer Research会议摘要
  2. Advancing Precise Diagnosis of Nasopharyngeal Carcinoma Through Endoscopy-Based Radiomics Analysis: Transitioning from Static Imaging to Video Analysis2024SSRN Electronic Journal预印本
  3. Advancing Precise Diagnosis of Nasopharyngeal Carcinoma Through Endoscopy-Based Radiomics Analysis: Transitioning from Static Imaging to Video Analysis2024SSRN Electronic Journal预印本
  4. Endoscopy-Based Radiomics Analysis for Precise Diagnosis of Nasopharyngeal Carcinoma: From Static Images to Video Analysis2024SSRN Electronic Journal预印本
  5. Additional file 2 of Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma2022Figshare数据集
  6. Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma: Data from an open-label, multicenter phase II basket study.2022Journal of Clinical Oncology会议摘要
  7. Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.2022Journal of Clinical Oncology会议摘要
  8. Clustering of nasopharyngeal carcinoma intensity modulated radiation therapy plans based on k-means algorithm and geometrical features2021Internatuinal Journal of Radiation Research论文

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 47 篇,占 1.6%。

牵头论文
47
2021–2025 年
牵头试验
24
任何状态,ClinicalTrials.gov
牵头的开放试验
12
正在或即将招募
作为研究中心的开放试验
8
由其他机构牵头
每年牵头的论文数
2021: 9920212022: 101020222023: 8820232024: 111120242025: 992025

天津有 2 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 20

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study
    分期
    III期
    开始
    2026-03
    登记号
    NCT07246330

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  2. 正在招募
    Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
    分期
    II期
    开始
    2026-03
    登记号
    NCT07457528

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  3. 正在招募
    Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
    分期
    II期
    开始
    2026-07
    登记号
    NCT07733830

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:天津医科大学肿瘤医院;另有 6 家列出的医院为研究中心北京、天津、太原、成都、沈阳、郑州

  4. 正在招募
    Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
    分期
    II期
    开始
    2025-09
    登记号
    NCT07038629

    年龄 70 岁 至 90 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  5. 正在招募
    dCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction Chemoimmunotherapy
    分期
    II期
    开始
    2025-11
    登记号
    NCT07162506

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  6. 正在招募
    Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
    分期
    II期
    开始
    2024-06
    登记号
    NCT06452602

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  7. 正在招募
    AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients
    分期
    II期
    开始
    2024-11
    登记号
    NCT06489197

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  8. 正在招募
    Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)
    分期
    III期
    开始
    2021-12
    登记号
    NCT04807673

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  9. 即将招募
    Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2026-06
    登记号
    NCT07493993

    年龄 18 岁 至 未注明(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  10. 即将招募
    Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2
    分期
    II期
    开始
    2026-04
    登记号
    NCT07531979

    年龄 18 岁 至 未注明(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  11. 即将招募
    Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2026-07
    登记号
    NCT07721103

    年龄 18 岁 至 未注明(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  12. 即将招募
    Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer
    分期
    II期
    开始
    2025-03
    登记号
    NCT06814158

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  13. 正在招募
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2026-08
    登记号
    NCT07700667

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心南京、南宁、南昌、哈尔滨、天津、太原、成都、昆明、汕头、沈阳、洛阳、石家庄、福州、西安、郑州、长春

  14. 正在招募
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    分期
    III期
    开始
    2025-03
    登记号
    NCT06644781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心临沂、北京、南宁、厦门、合肥、哈尔滨、天津、安阳、成都、扬州、新乡、杭州、武汉、汕头、沈阳、洛阳、济南、济宁、福州、郑州、长春

  15. 正在招募
    Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2024-03
    登记号
    NCT06342167

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心台州、天津、安阳、新乡、福州、银川

  16. 正在招募
    Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
    分期
    II期
    开始
    2024-10
    登记号
    NCT06637163

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属中山医院;另有 4 家列出的医院为研究中心上海、天津、杭州、汕头、沈阳

  17. 正在招募
    Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
    分期
    未注明
    开始
    2022-07
    登记号
    NCT05443841

    年龄未注明(登记的条件)

    牵头:复旦大学附属肿瘤医院;另有 8 家列出的医院为研究中心上海、南通、合肥、天津、泰州、石家庄、西安、郑州

  18. 正在招募
    Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
    分期
    III期
    开始
    2019-09
    登记号
    NCT04135664

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:上海市胸科医院;另有 5 家列出的医院为研究中心上海、南昌、天津

  19. 即将招募
    Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma
    分期
    未注明
    开始
    2026-09
    登记号
    NCT07769658

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:郑州大学第一附属医院;另有 5 家列出的医院为研究中心上海、天津、广州、成都、昆明、郑州

  20. 即将招募
    A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.
    分期
    I/II期
    开始
    2023-12
    登记号
    NCT06136988

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心天津

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫治疗新辅助与综合治疗放疗
论文中的科室放疗科肿瘤内科影像/核医学科消化/肝病科
牵头的论文47
  1. Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: a multicenter, randomized, parallel-controlled, phase II clinical t2025BMC cancer免费全文
  2. Prognostic role of the pathological status following neoadjuvant chemoradiotherapy and surgery in esophageal squamous cell carcinoma.2025BMC cancer免费全文
  3. Anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open-label, phase 1b clinical trial.2025Cancer免费全文
  4. LAG3 as a marker of immune activation in esophageal squamous carcinoma treated with concurrent chemoradiotherapy.2025Cancer immunology, immunotherapy : CII免费全文
  5. Immunochemotherapy plus radiotherapy versus immunochemotherapy alone as first-line treatment for treatment-naïve, advanced esophageal squamous cell carcinoma (AEC-ICR-1st): A multi-center cohort study.2025Cancer letters
  6. Multi-Institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma.2025Cancer medicine免费全文
  7. Spectral CT-based nomogram for evaluation of neoadjuvant chemotherapy response in esophageal squamous cell carcinoma.2025European radiology
  8. IL-15 signaling via cis- and trans-presentation to progenitor-exhausted CD8+ T cells enhances radio-immunotherapy efficacy in ESCC.2025Journal of nanobiotechnology免费全文
  9. Retrospective comparative study of video- and robot-assisted esophagectomy after neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.2025Surgical endoscopy
  10. Combined score based on plasma fibrinogen and platelet-lymphocyte ratio as a prognostic biomarker in esophageal squamous cell carcinoma.2024BMC cancer免费全文
  11. Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study.2024Cancer
  12. A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial.2024Cancer cell
  13. Survival benefit and spatial properties of tertiary lymphoid structures in esophageal squamous cell carcinoma with neoadjuvant therapies.2024Cancer letters
  14. Neoadjuvant chemoimmunotherapy was associated with better short-term survival of patients with locally advanced esophageal squamous cell carcinoma compared to neoadjuvant chemoradiotherapy.2024Cancer medicine免费全文
  15. A spatiotemporal comparative analysis on tumor immune microenvironment characteristics between neoadjuvant chemotherapy and preoperative immunotherapy for ESCC.2024Cell death & disease免费全文
  16. Feasibility and Safety of PD-1 Blockades Among Elderly Patients with Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Study.2024Drug design, development and therapy免费全文
  17. Clinical prognostication and immunotherapy response prediction in esophageal squamous cell carcinoma using the DNA damage repair-associated signature.2024Environmental toxicology
  18. Integrated machine learning developed a prognosis-related gene signature to predict prognosis in oesophageal squamous cell carcinoma.2024Journal of cellular and molecular medicine免费全文
  19. Neoadjuvant chemoimmunotherapy followed by robot esophagectomy has no effect on short-term results compared with surgery alone.2024Thoracic cancer免费全文
  20. Role of deubiquitinase JOSD2 in the pathogenesis of esophageal squamous cell carcinoma.2024World journal of gastroenterology免费全文
  21. Predictive and prognostic markers from endoscopic ultrasound with biopsies during definitive chemoradiation therapy in esophageal squamous cell carcinoma.2023BMC cancer免费全文
  22. High expression of PPFIA1 in human esophageal squamous cell carcinoma correlates with tumor metastasis and poor prognosis.2023BMC cancer免费全文
  23. Establishment of a risk model by integrating hypoxia genes in predicting prognosis of esophageal squamous cell carcinoma.2023Cancer medicine免费全文
  24. USP4 promotes the proliferation, migration, and invasion of esophageal squamous cell carcinoma by targeting TAK1.2023Cell death & disease免费全文
  25. Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer.2023Frontiers in immunology免费全文
  26. Effects of PEG in patients with esophageal squamous cell carcinoma during concurrent chemoradiotherapy: a prospective study.2023Gastrointestinal endoscopy
  27. Efficacy of PD-1/PD-L1 inhibitors in advanced gastroesophageal cancer based on characteristics: a meta-analysis.2023Immunotherapy
  28. Radiotherapy plus camrelizumab affects peripheral CD8 T-cell differentiation subsets expressing PD-1, TIGIT, and CTLA-4 in esophageal squamous cell carcinoma.2023Journal of leukocyte biology
  29. Comparison of clinicopathological features and prognostic significance between synchronous multiple primary and solitary esophageal squamous cell carcinomas.2022BMC cancer免费全文
  30. CXCR4 promotes the growth and metastasis of esophageal squamous cell carcinoma as a critical downstream mediator of HIF-1α.2022Cancer science免费全文
  31. Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico免费全文
  32. Comparison of dynamic changes in the peripheral CD8+ T cells function and differentiation in ESCC patients treated with radiotherapy combined with anti-PD-1 antibody or concurrent chemoradiotherapy.2022Frontiers in immunology免费全文
  33. Single cell sequencing revealed the mechanism of PD-1 resistance affected by the expression profile of peripheral blood immune cells in ESCC.2022Frontiers in immunology免费全文
  34. Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade.2022Oncoimmunology免费全文
  35. A retrospective study comparing definitive chemoradiotherapy vs. chemoradiotherapy followed by surgery in T4 esophageal squamous cell carcinoma patients who were downstaged after neochemoradiotherapy.2022Radiation oncology (London, England)免费全文
  36. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: A pha2022Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRCT
  37. Development and validation of nodal staging score in pN0 patients with esophageal squamous cell carcinoma: A population study from the SEER database and a single-institution cohort.2022Thoracic cancer免费全文
  38. Is adjuvant immunotherapy a new standard for non-pathological complete response patients with resectable esophageal squamous cell carcinoma?2022Thoracic cancer免费全文
  39. A nomogram to predict lymph node metastasis risk for early esophageal squamous cell carcinoma.2021BMC cancer免费全文
  40. The prognostic performance of the log odds of positive lymph nodes in patients with esophageal squamous cell carcinoma: A population study of the US SEER database and a Chinese single-institution cohort.2021Cancer medicine免费全文
  41. High-mobility group AT-hook 2 promotes growth and metastasis and is regulated by miR-204-5p in oesophageal squamous cell carcinoma.2021European journal of clinical investigation
  42. Spatial Distribution and Predictive Significance of Dendritic Cells and Macrophages in Esophageal Cancer Treated With Combined Chemoradiotherapy and PD-1 Blockade.2021Frontiers in immunology免费全文
  43. TGIF1 plays a carcinogenic role in esophageal squamous cell carcinoma through the Wnt/β‑catenin and Akt/mTOR signaling pathways.2021International journal of molecular medicine免费全文
  44. Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study.2021Oncoimmunology免费全文
  45. Lymph node dissection around left recurrent laryngeal nerve: robot-assisted vs. video-assisted McKeown esophagectomy for esophageal squamous cell carcinoma.2021Surgical endoscopy免费全文
  46. Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.2021The oncologist免费全文
  47. The PSMD14 inhibitor Thiolutin as a novel therapeutic approach for esophageal squamous cell carcinoma through facilitating SNAIL degradation.2021Theranostics免费全文
中文论文(未计入)2
  1. [The influence of Ras-associated binding protein 23 knockdown on the migration and invasion of esophageal squamous cell carcinoma cells and its mechanism].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
  2. [Research progress and challenges of neoadjuvant therapy for esophageal squamous cell carcinoma].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)50
  1. Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC正在招募NCT07733830牵头方II期2026-07 启动
  2. Early Response-guided Sequential Radiotherapy After Chemoimmunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma即将招募NCT07721103牵头方II期2026-07 启动
  3. Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study正在招募NCT07246330牵头方III期2026-03 启动
  4. Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC正在招募NCT07457528牵头方II期2026-03 启动
  5. Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma即将招募NCT07493993牵头方II期2026-06 启动
  6. Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2即将招募NCT07531979牵头方II期2026-04 启动
  7. Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC正在招募NCT07038629牵头方II期2025-09 启动
  8. Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer即将招募NCT06814158牵头方II期2025-03 启动
  9. dCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction Chemoimmunotherapy正在招募NCT07162506牵头方II期2025-11 启动
  10. Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.正在招募NCT06452602牵头方II期2024-06 启动
  11. AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients正在招募NCT06489197牵头方II期2024-11 启动
  12. Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)正在招募NCT04807673牵头方III期2021-12 启动
  13. Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC状态不明NCT06061146牵头方II期2023-10 启动
  14. Conversion of Tislelizumab Combined With Chemotherapy in Unresectable Esophageal Squamous Cell Carcinoma状态不明NCT05449483牵头方II期2022-05 启动
  15. A Phase II Study of CRT Combined With QL1706 in ESCC Patients状态不明NCT05490719牵头方II期2022-08 启动
  16. Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma状态不明NCT05476380牵头方II期2021-02 启动
  17. An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody状态不明NCT04866381牵头方II期2021-04 启动
  18. Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)状态不明NCT04389177牵头方II期2020-07 启动
  19. Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma状态不明NCT05637268牵头方II期2020-11 启动
  20. To Compare the Effect of Different Nutritional Pathways on Improving Nutritional Status of Esophageal Cancer Patients Undergoing Chemoradiotherapy已完成NCT04199832牵头方2019-12 启动
  21. Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC状态不明NCT03671265牵头方不分期2018-09 启动
  22. Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.已完成NCT06190652牵头方2018-10 启动
  23. Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC已完成NCT03222440牵头方不分期2017-07 启动
  24. The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma已完成NCT06241066牵头方2014-01 启动
  25. SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma正在招募NCT07700667研究中心II期2026-08 启动
  26. Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma即将招募NCT07769658研究中心2026-09 启动
  27. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)正在招募NCT06644781研究中心III期2025-03 启动
  28. Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC正在招募NCT06637163研究中心II期2024-10 启动
  29. Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma正在招募NCT06342167研究中心II期2024-03 启动
  30. A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.即将招募NCT06136988研究中心I/II期2023-12 启动
  31. Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)正在招募NCT05443841研究中心2022-07 启动
  32. Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma正在招募NCT04135664研究中心III期2019-09 启动
  33. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT06010303研究中心II期2023-11 启动
  34. Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma已完成NCT04974047研究中心II期2021-08 启动
  35. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT04732494研究中心II期2021-03 启动
  36. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma进行中,不再招募NCT04848753研究中心III期2021-05 启动
  37. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).已终止NCT04949256研究中心III期2021-07 启动
  38. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy已完成NCT04543617研究中心III期2020-09 启动
  39. Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer状态不明NCT04426955研究中心III期2020-06 启动
  40. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma已完成NCT04540211研究中心III期2020-10 启动
  41. Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)已完成NCT04210115研究中心III期2020-02 启动
  42. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma已完成NCT03957590研究中心III期2019-06 启动
  43. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
  44. Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma状态不明NCT03817567研究中心I/II期2018-07 启动
  45. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03783442研究中心III期2018-12 启动
  46. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  47. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)已完成NCT02649361研究中心II期2016-01 启动
  48. Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma已完成NCT02395705研究中心III期2015-06 启动
  49. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma状态不明NCT02611700研究中心III期2015-11 启动
  50. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma状态不明NCT01232374研究中心II期2010-09 启动
PubMed 以外找到的论文(未计入)57
  1. 2125P A phase II study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma2025Annals of Oncology论文
  2. 223. CAMRELIZUMAB AND CHEMOTHERAPY AS NEOADJUVANT TREATMENT FOR LOCALLYADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)A SINGLE-ARM, PHASE II TRIAL2025Diseases of the Esophagus论文
  3. 251. PRELIMINARY SURGICAL OUTCOMES FROM MULTICENTER, RANDOMIZED PHASE III TRIAL (SCIENCE): IMPACT OF NEOADJUVANT SINTILIMAB-BASED REGIMENS ON RESECTABLE LOCALLY ADVANCED ESCC2025Diseases of the Esophagus论文
  4. 337. RETROSPECTIVE COHORT STUDY OF VIDEO- AND ROBOT-ASSISTED ESOPHAGECTOMY AFTER NEOADJUVANT CHEMORADIOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025Diseases of the Esophagus论文
  5. 347. THE LYMPH NODE DISSECTION OF NO.106RECL WAS ASSOCIATED WITH BETTER LONG-TERM SURVIVAL FOR ESOPHAGEAL CANCER AFTER ROBOT-ASSISTED ESOPHAGECTOMY2025Diseases of the Esophagus论文
  6. 349. PATHOLOGIC COMPLETE RESPONSE IN ESOPHAGEAL SQUAMOUS CELL CANCER: DO DIVERSE NEOADJUVANT MODALITIES PREDICT PROGNOSTIC DIFFERENCES?2025Diseases of the Esophagus论文
  7. 379. HEALTH-RELATED QUALITY OF LIFE FOLLOWING ROBOTIC VERSUS THORACOSCOPIC ESOPHAGECTOMY: A PRESPECIFIED SECONDARY ANALYSIS OF THE MULTICENTER REVATE TRIAL2025Diseases of the Esophagus论文
  8. 486eTiP Interim results and ctDNA biomarker analysis from the phase III SCIENCE trial: Neoadjuvant chemotherapy or chemoradiotherapy with/without sintilimab for resectable locally advanced esophageal squamous cell carcinoma2025Annals of Oncology论文
  9. 486eTiP Interim results and ctDNA biomarker analysis from the phase III SCIENCE trial: Neoadjuvant chemotherapy or chemoradiotherapy with/without sintilimab for resectable locally advanced esophageal squamous cell carcinoma2025Annals of Oncology论文
  10. 963P SC-101, a Nectin-4-targeting peptide-drug conjugate (PDC), in patients (pts) with advanced or metastatic solid tumors: Results from dose escalation study2025Annals of Oncology论文
  11. A Multi-Dimensional Deep Ensemble Learning Model Predicts Pathological Response and Treatment Outcomes to Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma Using Pretreatment CT Images: A Multicenter, Retrospective Cohort 2025International Journal of Radiation Oncology*Biology*Physics论文
  12. Impact of muscle mass loss on survival during neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma: A multi-center retrospective study in China (TIMES study).2025Journal of Clinical Oncology论文
  13. Knockdown of DNAJC12 slows tumor progression and affects tumor radiosensitivity in esophageal squamous cell carcinoma2025Molecular & cellular biomechanics论文
  14. Long-term outcomes of toripalimab plus chemotherapy and radiotherapy for treatment-naive advanced esophageal squamous cell carcinoma: Results from a phase II trial.2025Journal of Clinical Oncology论文
  15. Preliminary results from the multicenter, randomized phase III trial (SCIENCE): Comparing chemotherapy plus sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy for neoadjuvant treatment in resectable locally advanced e2025Journal of Clinical Oncology论文
  16. Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis2025Journal of Clinical Oncology会议摘要
  17. 1414P Iparomlimab and tuvonralimab (QL1706) with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: An open-label phase II study2024Annals of Oncology论文
  18. 552. COMPARING ROBOTIC ESOPHAGECTOMY TO VIDEO-ASSISTED THORACOSCOPIC ESOPHAGECTOMY FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA: RESULTS FROM THE REVATE RANDOMIZED CLINICAL TRIAL2024Diseases of the Esophagus论文
  19. ALOX12B and PRMT5 inhibit stemness and EMT in esophageal squamous cell carcinoma by promoting decorin expression2024Research Square预印本
  20. Abstract CT227: Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody toripalimab, in patients with advanced malignant tumors: A phase Ib/II, open-label, multicenter, dose escalation/expansion study2024Cancer Research会议摘要
  21. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncology会议摘要
  22. Conversion surgery for tislelizumab combined chemotherapy for T4a/N3 esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study.2024Journal of Clinical Oncology会议摘要
  23. Extracellular Hmgb1 Increases Radioresistance of Esophageal Squamous Cell Carcinoma Through Stabilizing Pd-L1 by Npm12024SSRN Electronic Journal预印本
  24. Multimodality Deep Learning Radiomics Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy2024International Journal of Radiation Oncology*Biology*Physics论文
  25. Neoadjuvant Immunotherapy combined with Chemoradiotherapy VS. Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma(cStageII-III): Study Protocol For A Multi-center Prospective Randomized Clinical Trial2024Research Square预印本
  26. Radiotherapy Combined with Chemoimmunotherapy vs. Chemoimmunotherapy Alone as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma with Oligometastasis at Initial Diagnosis2024International Journal of Radiation Oncology*Biology*Physics论文
  27. Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: A multicenter, randomized, parallel-controlled, phase II clinical t2024Journal of Clinical Oncology会议摘要
  28. 145P Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)2023Annals of Oncology论文
  29. 153. PROPENSITY MATCHING ANALYSIS OF NEOADJUVANT CHEMORADIOTHERAPY AND NEOADJUVANT IMMUNOTHERAPY COMBINED WITH CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED ESCC2023Diseases of the Esophagus论文
  30. 1558P Preoperative pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma (ESCC): The phase II Keystone-001 trial2023Annals of Oncology论文
  31. 1573P Involved field and elective nodal irradiation presented similar treatment efficiency in concurrent chemoradiation for locally advanced ESCC2023Annals of Oncology论文
  32. Additional file 2 of FBXW7 loss of function promotes esophageal squamous cell carcinoma progression via elevating MAP4 and ERK phosphorylation2023Figshare数据集
  33. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  34. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  35. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  36. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  37. Advantages of nasogastric tube feeding during neoadjuvant concurrent chemoradiotherapy for esophageal cancer: A retrospective study2023Radiation Medicine and Protection论文
  38. Camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II trial.2023Journal of Clinical Oncology会议摘要
  39. Deep learning-based prediction model for predicting the tumor origin of cancers of unknown primary.2023Journal of Clinical Oncology会议摘要
  40. KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.2023Journal of Clinical Oncology会议摘要
  41. O-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)2023Annals of Oncology论文
  42. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figshare数据集
  43. CT-Based Deep Learning Model for Predicting Local Recurrence-Free Survival in Esophageal Squamous Cell Carcinoma Patients Received Concurrent Chemo-Radiotherapy: A Multicenter Study2022International Journal of Radiation Oncology*Biology*Physics论文
  44. Concurrent Chemoradiation of Different Doses (50.4 Gy vs. 59.4 Gy) and Different Target Field (ENI vs. IFI) for Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Randomized, Multicenter Phase Ⅲ Clinical Trial2022International Journal of Radiation Oncology*Biology*Physics论文
  45. Diagnostic efficacy of deep learning-based prediction of origin for patients with cancers of unknown primary.2022Journal of Clinical Oncology会议摘要
  46. Effectiveness of S-1–Based Chemoradiotherapy and S-1 Consolidation in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Multicenter Randomized Phase III Clinical Trial2022International Journal of Radiation Oncology*Biology*Physics论文
  47. Establishment of a risk model by integrating hypoxia genes in predicting prognosis of esophageal squamous cell carcinoma2022Research Square预印本
  48. Establishment of a risk model by integrating hypoxia genes in predicting prognosis of esophageal squamous cell carcinoma2022Research Square预印本
  49. High expression of PPFIA1 in human esophageal squamous cell carcinoma correlates with tumor progression and poor prognosis2022Research Square预印本
  50. 166TiP Pembrolizumab combined with neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy followed surgery for locally advanced esophageal squamous cell carcinoma: Protocol for a multi-center, prospective, randomized-controlled, phas2021Annals of Oncology论文
  51. Addition of Induction or Consolidation Chemotherapy in Definitive Concurrent Chemoradiotherapy vs. Concurrent Chemoradiotherapy Alone for Patients With Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis2021International Journal of Radiation Oncology*Biology*Physics论文
  52. High Expression of PPFIA1 Is Associated With Tumor Progression and a Poor Prognosis in Esophageal Squamous Cell Carcinoma2021Research Square预印本
  53. Identification of a Hypoxia-Related Gene Signature and Establishment of a Nomogram for Predicting Prognosis in Esophageal Squamous Cell Carcinoma2021SSRN Electronic Journal预印本
  54. LBA3 Safety and efficacy of pembrolizumab combined with paclitaxel and cisplatin as a neoadjuvant treatment for locally advanced resectable (stage III) esophageal squamous cell carcinoma (Keystone-001): Interim analysis of a prospective, si2021Annals of Oncology论文
  55. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figshare数据集
  56. Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell cancer.2021Journal of Clinical Oncology会议摘要
  57. The Prognostic Performance of Log Odds of Positive Lymph Nodes in Patients with Esophageal Squamous Cell Carcinoma: A Population Study of the US SEER Database and a Chinese Single-Institution Cohort2021SSRN Electronic Journal预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 88 篇,占 0.6%。

牵头论文
88
2021–2025 年
牵头试验
37
任何状态,ClinicalTrials.gov
牵头的开放试验
11
正在或即将招募
作为研究中心的开放试验
9
由其他机构牵头
每年牵头的论文数
2021: 222220212022: 161620222023: 161620232024: 191920242025: 14142025

天津有 4 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 20

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
    分期
    III期
    开始
    2026-06
    登记号
    NCT07475026

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  2. 正在招募
    Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
    分期
    II期
    开始
    2026-03
    登记号
    NCT07560488

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  3. 正在招募
    IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus
    分期
    不分期
    开始
    2026-05
    登记号
    NCT07799922

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  4. 正在招募
    Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC
    分期
    II期
    开始
    2026-09
    登记号
    NCT07801287

    年龄 18 岁 至 未注明(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  5. 正在招募
    Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma
    分期
    未注明
    开始
    2026-10
    登记号
    NCT07840092

    年龄 18 岁 至 未注明(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  6. 正在招募
    Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer
    分期
    II期
    开始
    2025-01
    登记号
    NCT06766643

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  7. 正在招募
    FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
    分期
    II期
    开始
    2025-09
    登记号
    NCT07012798

    年龄 18 岁 至 未注明(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  8. 正在招募
    Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
    分期
    II期
    开始
    2025-08
    登记号
    NCT07099274

    年龄 18 岁 至 未注明(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  9. 正在招募
    Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study
    分期
    II期
    开始
    2024-03
    登记号
    NCT06301399

    年龄 17 岁 至 79 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  10. 即将招募
    Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC
    分期
    II期
    开始
    2026-10
    登记号
    NCT07847671

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  11. 即将招募
    Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
    分期
    II期
    开始
    2025-09
    登记号
    NCT07157306

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  12. 正在招募
    MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
    分期
    I/II期
    开始
    2026-04
    登记号
    NCT07479485

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心北京、南京、天津、福州、郑州

  13. 正在招募
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    分期
    I/II期
    开始
    2026-05
    登记号
    NCT07547553

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、沈阳、福州、蚌埠、长春

  14. 正在招募
    HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence
    分期
    II期
    开始
    2025-01
    登记号
    NCT06812039

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:复旦大学附属肿瘤医院;另有 2 家列出的医院为研究中心上海、天津、福州

  15. 正在招募
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    分期
    I期
    开始
    2025-11
    登记号
    NCT07176650

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、海口、石家庄、福州、蚌埠、西安、郑州、长春

  16. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  17. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

  18. 正在招募
    CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
    分期
    I期
    开始
    2023-10
    登记号
    NCT06560827

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、武汉、沈阳、福州、郑州、长沙

  19. 正在招募
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    分期
    I/II期
    开始
    2021-11
    登记号
    NCT05024214

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心上海、北京、哈尔滨、大连、天津、广州、杭州、沈阳、珠海、福州、蚌埠、郑州、长春

  20. 即将招募
    A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
    分期
    III期
    开始
    2025-01
    登记号
    NCT06779461

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、兰州、南京、天津、广州、蚌埠、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科肿瘤内科病理/检验科影像/核医学科
牵头的论文88
  1. LI-RADS nonradiation treatment response assessment version 2024: diagnostic performance in HCC treated with transarterial chemoembolization.2026European radiology
  2. Minimalistic Implant for Percutaneous Magnetic Hyperthermia-Based Combination Therapy of Hepatocellular Carcinoma.2025ACS applied materials & interfaces
  3. Aristolochic acids-hijacked p53 promotes liver cancer cell growth by inhibiting ferroptosis.2025Acta pharmacologica Sinica免费全文
  4. Inhibition of nuclear receptor coactivator 5 overcomes acquired lenvatinib resistance driven by protein kinase B-mammalian target of rapamycin signaling in hepatocellular carcinoma.2025Anti-cancer drugs免费全文
  5. 18F-FDG PET/CT-based intratumoral and peritumoral radiomics combining ensemble learning for prognosis prediction in hepatocellular carcinoma: a multi-center study.2025BMC cancer免费全文
  6. Survival benefit of adjuvant chemotherapy and individualized prognosis in resected cHCC-CCA.2025Bioscience trends
  7. Tumor-derived CCL15 regulates RNA m6A methylation in cancer-associated fibroblasts to promote hepatocellular carcinoma growth.2025Cancer letters
  8. CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance.2025Cancer research
  9. Inhibition of Wnt/β-catenin increases anti-tumor activity by synergizing with sorafenib in hepatocellular carcinoma.2025Cell death & disease免费全文
  10. Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study.2025Clinical cancer research : an official journal of the American Association for Cancer Research
  11. Macrophage membrane-based biomimetic nanocarrier system for enhanced immune activation and combination therapy in liver cancer.2025Drug delivery and translational research
  12. Predictors of recurrence after conversion therapy in unresectable hepatocellular carcinoma treated with HAIC, bevacizumab, and sintilimab.2025Frontiers in immunology免费全文
  13. Triple therapy revolutionizes treatment paradigms for previously untreatable HCC complicated by high-flow hepatic arteriovenous fistulas.2025Frontiers in immunology免费全文
  14. Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging.2025Frontiers in immunology免费全文
  15. Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study.2025Hepatology international
  16. Efficacy and Safety of CT-guided Percutaneous Cryoablation for Hepatocellular Carcinoma at High-risk Sites.2024Academic radiology
  17. Bevacizumab induces ferroptosis and enhances CD8+ T cell immune activity in liver cancer via modulating HAT1 and increasing IL-9.2024Acta pharmacologica Sinica免费全文
  18. Artificial Intelligence-Driven Platform: Unveiling Critical Hepatic Molecular Alterations in Hepatocellular Carcinoma Development.2024Advanced healthcare materials
  19. CDCA8 Facilitates Tumor Proliferation and Predicts a Poor Prognosis in Hepatocellular Carcinoma.2024Applied biochemistry and biotechnology
  20. ARHGAP18 is Upregulated by Transcription Factor GATA1 Promotes the Proliferation and Invasion in Hepatocellular Carcinoma.2024Applied biochemistry and biotechnology
  21. 18F-FDG PET/CT-based habitat radiomics combining stacking ensemble learning for predicting prognosis in hepatocellular carcinoma: a multi-center study.2024BMC cancer免费全文
  22. Lenvatinib targets STAT-1 to enhance the M1 polarization of TAMs during hepatocellular carcinoma progression.2024BMC cancer免费全文
  23. From bioinformatics to clinical applications: a novel prognostic model of cuproptosis-related genes based on single-cell RNA sequencing data in hepatocellular carcinoma.2024BMC immunology免费全文
  24. Sorafenib combined with TACE improves survival in patients with hepatocellular carcinoma with vascular invasion.2024Bioscience trends
  25. Large language model produces high accurate diagnosis of cancer from end-motif profiles of cell-free DNA.2024Briefings in bioinformatics免费全文
  26. Language model enables end-to-end accurate detection of cancer from cell-free DNA.2024Briefings in bioinformatics免费全文
  27. Anti-PD-L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy-refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study.2024Cancer
  28. Macrophage-coated tumor cluster aggravates hepatoma invasion and immunotherapy resistance via generating local immune deprivation.2024Cell reports. Medicine免费全文
  29. Integrated single-cell and bulk transcriptome analysis of R-loop score-based signature with regard to immune microenvironment, lipid metabolism and prognosis in HCC.2024Frontiers in immunology免费全文
  30. A preliminary study of optimal treatment response rates in patients undergoing hepatic arterial infusion chemotherapy combined with molecular targeting and immunotherapy.2024Frontiers in immunology免费全文
  31. Tertiary lymphoid structures as a potential prognostic biomarker for combined hepatocellular-cholangiocarcinoma.2024Hepatology international免费全文
  32. Dual-Drug Loaded Nanobubbles Combined with Sonodynamic and Chemotherapy for Hepatocellular Carcinoma Therapy.2024International journal of nanomedicine免费全文
  33. Liver cancer-specific mutations in functional domains of ADAR2 lead to the elevation of coding and non-coding RNA editing in multiple tumor-related genes.2024Molecular genetics and genomics : MGG
  34. Lenvatinib, sintilimab combined interventional treatment vs bevacizumab, sintilimab combined interventional treatment for intermediate-advanced unresectable hepatocellular carcinoma.2024World journal of gastroenterology免费全文
  35. Predictive Factors of Treatment Outcomes After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in the Hepatocaval Confluence: A Propensity Score Matching Analysis.2023Academic radiology
  36. Aspirin modulates succinylation of PGAM1K99 to restrict the glycolysis through NF-κB/HAT1/PGAM1 signaling in liver cancer.2023Acta pharmacologica Sinica免费全文
  37. Heat shock protein family A member 8 serving as a co-activator of transcriptional factor ETV4 up-regulates PHLDA2 to promote the growth of liver cancer.2023Acta pharmacologica Sinica免费全文
  38. Aspirin triggers ferroptosis in hepatocellular carcinoma cells through restricting NF-κB p65-activated SLC7A11 transcription.2023Acta pharmacologica Sinica免费全文
  39. The Combination of R848 with Sorafenib Enhances Antitumor Effects by Reprogramming the Tumor Immune Microenvironment and Facilitating Vascular Normalization in Hepatocellular Carcinoma.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  40. Identification of topoisomerase 2A as a novel bone metastasis-related gene in liver hepatocellular carcinoma.2023Aging免费全文
  41. Fc fragment of IgG binding protein is correlated with immune infiltration levels in hepatocellular carcinoma.2023Biomolecules & biomedicine免费全文
  42. Comparison of the long-term outcomes of patients with hepatocellular carcinoma within the Milan criteria treated by ablation, resection, or transplantation.2023Cancer medicine免费全文
  43. Pan-cancer analysis of cuproptosis-promoting gene signature from multiple perspectives.2023Clinical and experimental medicine
  44. Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression.2023Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  45. Thioredoxin facilitates hepatocellular carcinoma stemness and metastasis by increasing BACH1 stability to activate the AKT/mTOR pathway.2023FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  46. Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study.2023Frontiers in immunology免费全文
  47. Intratumoral microbial heterogeneity affected tumor immune microenvironment and determined clinical outcome of HBV-related HCC.2023Hepatology (Baltimore, Md.)免费全文
  48. Exploring the molecular characteristics of the malignant potential of gastric adenocarcinoma with enteroblastic differentiation.2023Histopathology
  49. Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial.2023Neoplasma
  50. miR-4270 suppresses hepatocellular carcinoma progression by inhibiting DNMT3A-mediated methylation of HGFAC promoter.2023PeerJ免费全文
  51. IFN-α inhibits HBV transcription and replication by promoting HDAC3-mediated de-2-hydroxyisobutyrylation of histone H4K8 on HBV cccDNA minichromosome in liver.2022Acta pharmacologica Sinica免费全文
  52. Serum long non-coding RNA SCARNA10 serves as a potential diagnostic biomarker for hepatocellular carcinoma.2022BMC cancer免费全文
  53. Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma.2022BMC gastroenterology免费全文
  54. Screening for Lipid-Metabolism-Related Genes and Identifying the Diagnostic Potential of ANGPTL6 for HBV-Related Early-Stage Hepatocellular Carcinoma.2022Biomolecules免费全文
  55. Elevated serum CA19-9 indicates severe liver inflammation and worse survival after curative resection in hepatitis B-related hepatocellular carcinoma.2022Bioscience trends
  56. PNO1 inhibits autophagy-mediated ferroptosis by GSH metabolic reprogramming in hepatocellular carcinoma.2022Cell death & disease免费全文
  57. DNAJC24 is a potential therapeutic target in hepatocellular carcinoma through affecting ammonia metabolism.2022Cell death & disease免费全文
  58. Spatiotemporal modulation of SMAD4 by HBx is required for cellular proliferation in hepatitis B-related liver cancer.2022Cellular oncology (Dordrecht, Netherlands)免费全文
  59. A Novel Ferroptosis-Related Long Non-Coding RNA Prognostic Signature Correlates With Genomic Heterogeneity, Immunosuppressive Phenotype, and Drug Sensitivity in Hepatocellular Carcinoma.2022Frontiers in immunology免费全文
  60. Single-Cell DNA Sequencing Reveals Punctuated and Gradual Clonal Evolution in Hepatocellular Carcinoma.2022Gastroenterology
  61. A nomogram based on a three pyroptosis gene model and clinical parameters for predicting prognosis of hepatocellular carcinoma.2022Gene
  62. Identification of a seven-gene signature predicting clinical outcome of liver cancer based on tumor mutational burden.2022Human cell
  63. Targeting delivery of synergistic dual drugs with elastic PEG-modified multi-functional nanoparticles for hepatocellular carcinoma therapy.2022International journal of pharmaceutics
  64. LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma.2022Medicine免费全文
  65. Decreased expression of SVEP1 is closely related to a cancer stem cell-like phenotype and poor prognosis in hepatocellular carcinoma.2022Neoplasma
  66. Mechanism of miR-424-5p promoter methylation in promoting epithelial-mesenchymal transition of hepatocellular carcinoma cells.2022The Kaohsiung journal of medical sciences免费全文
  67. Hepatitis B Virus X Protein Modulates Chemokine CCL15 Upregulation in Hepatocellular Carcinoma.2021Anti-cancer agents in medicinal chemistry
  68. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.2021BMC cancer免费全文
  69. Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway.2021BioMed research international免费全文
  70. Aspirin modulates 2-hydroxyisobutyrylation of ENO1K281 to attenuate the glycolysis and proliferation of hepatoma cells.2021Biochemical and biophysical research communications
  71. Replication Factor C4 in human hepatocellular carcinoma: A potent prognostic factor associated with cell proliferation.2021Bioscience trends
  72. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma.2021Bioscience trends
  73. Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China.2021Bioscience trends
  74. MCM4 in human hepatocellular carcinoma: a potent prognostic factor associated with cell proliferation.2021Bioscience trends
  75. Development of an AI system for accurately diagnose hepatocellular carcinoma from computed tomography imaging data.2021British journal of cancer免费全文
  76. Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma.2021Cancer gene therapy
  77. Angiotensin-converting enzyme inhibitors have adverse effects in anti-angiogenesis therapy for hepatocellular carcinoma.2021Cancer letters
  78. DTYMK promote hepatocellular carcinoma proliferation by regulating cell cycle.2021Cell cycle (Georgetown, Tex.)免费全文
  79. PNO1 regulates autophagy and apoptosis of hepatocellular carcinoma via the MAPK signaling pathway.2021Cell death & disease免费全文
  80. Shc3 promotes hepatocellular carcinoma stemness and drug resistance by interacting with β-catenin to inhibit its ubiquitin degradation pathway.2021Cell death & disease免费全文
  81. MicroRNA-361 suppresses the biological processes of hepatic stellate cells in HBV-relative hepatic fibrosis by NF-kappaB p65.2021Cells & development
  82. Mild chronic hypoxia-induced HIF-2α interacts with c-MYC through competition with HIF-1α to induce hepatocellular carcinoma cell proliferation.2021Cellular oncology (Dordrecht, Netherlands)免费全文
  83. Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS.2021European radiology
  84. Identifying the biomarkers and pathways associated with hepatocellular carcinoma based on an integrated analysis approach.2021Liver international : official journal of the International Association for the Study of the Liver
  85. LDLR inhibition promotes hepatocellular carcinoma proliferation and metastasis by elevating intracellular cholesterol synthesis through the MEK/ERK signaling pathway.2021Molecular metabolism免费全文
  86. Imbalance of TGF-β1/BMP-7 pathways induced by M2-polarized macrophages promotes hepatocellular carcinoma aggressiveness.2021Molecular therapy : the journal of the American Society of Gene Therapy免费全文
  87. Plasma heat shock protein 90alpha as a biomarker for the diagnosis of liver cancer: in patients with different clinicopathologic characteristics.2021World journal of surgical oncology免费全文
  88. Comparison of Liver Transplantation and Liver Resection for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus Type I and Type II.2021Yonsei medical journal免费全文
中文论文(未计入)3
  1. [The influence of knocking down the expression of low-density lipoprotein receptor associated proteins on the vascular abnormalities in hepatocellular carcinoma and its mechanisms].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
  2. [Changes and challenges of surgical treatment strategy for hepatocellular carcinoma].2021Zhonghua wai ke za zhi [Chinese journal of surgery]
  3. [Application of superb microvascular imaging in focal liver lesions].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
它在 ClinicalTrials.gov 上的全部试验(任何状态)66
  1. A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence正在招募NCT07475026牵头方III期2026-06 启动
  2. Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma正在招募NCT07560488牵头方II期2026-03 启动
  3. Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC正在招募NCT07801287牵头方II期2026-09 启动
  4. Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC即将招募NCT07847671牵头方II期2026-10 启动
  5. IRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus正在招募NCT07799922牵头方不分期2026-05 启动
  6. Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma正在招募NCT07840092牵头方2026-10 启动
  7. Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma正在招募NCT07099274牵头方II期2025-08 启动
  8. FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma正在招募NCT07012798牵头方II期2025-09 启动
  9. Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer正在招募NCT06766643牵头方II期2025-01 启动
  10. Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma即将招募NCT07157306牵头方II期2025-09 启动
  11. Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study正在招募NCT06301399牵头方II期2024-03 启动
  12. Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI进行中,不再招募NCT07658105牵头方II期2026-06 启动
  13. Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma(uHCC).状态不明NCT06375486牵头方II期2024-03 启动
  14. Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma已暂停NCT06405061牵头方II期2024-05 启动
  15. Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy状态不明NCT05856864牵头方I期2024-06 启动
  16. HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma状态不明NCT05864755牵头方II期2023-06 启动
  17. Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.已完成NCT05807776牵头方II期2023-04 启动
  18. Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients状态不明NCT06370065牵头方II期2023-04 启动
  19. HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma状态不明NCT05821361牵头方II期2023-08 启动
  20. A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma进行中,不再招募NCT05644379牵头方I期2022-11 启动
  21. Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma状态不明NCT05616390牵头方II期2022-11 启动
  22. HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma进行中,不再招募NCT05621499牵头方不分期2022-12 启动
  23. Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma状态不明NCT05519410牵头方II期2022-08 启动
  24. HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC状态不明NCT05029973牵头方II期2021-05 启动
  25. Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma状态不明NCT04834986牵头方II期2021-04 启动
  26. Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma已完成NCT04701060牵头方II期2021-01 启动
  27. TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors状态不明NCT06487663牵头方不分期2020-10 启动
  28. Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver Cancer进行中,不再招募NCT07298538牵头方2019-01 启动
  29. PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC状态不明NCT04273100牵头方II期2019-11 启动
  30. Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma状态不明NCT03398122牵头方不分期2017-11 启动
  31. Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)状态不明NCT03046979牵头方II期2016-12 启动
  32. Metformin Plus Sorafenib for Advanced HCC状态不明NCT02672488牵头方II期2015-12 启动
  33. Study on Effectiveness and Safety of Hepatocellular Carcinoma Patients Treated With CyberKnife状态不明NCT02363218牵头方II期2014-05 启动
  34. A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma状态不明NCT01758679牵头方IV期2012-01 启动
  35. Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas状态不明NCT01393093牵头方不分期2011-03 启动
  36. Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas (TACE-KMG)状态不明NCT01393197牵头方不分期2011-03 启动
  37. Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional Therapy状态不明NCT05975463牵头方(推断)II期2023-09 启动
  38. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC正在招募NCT07547553研究中心I/II期2026-05 启动
  39. MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)正在招募NCT07479485研究中心I/II期2026-04 启动
  40. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  41. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma正在招募NCT07176650研究中心I期2025-11 启动
  42. HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence正在招募NCT06812039研究中心II期2025-01 启动
  43. A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma即将招募NCT06779461研究中心III期2025-01 启动
  44. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  45. CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection正在招募NCT06560827研究中心I期2023-10 启动
  46. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors正在招募NCT05024214研究中心I/II期2021-11 启动
  47. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere进行中,不再招募NCT06900543研究中心III期2025-04 启动
  48. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)进行中,不再招募NCT05904886研究中心III期2023-09 启动
  49. Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)状态不明NCT05594927研究中心III期2022-12 启动
  50. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma进行中,不再招募NCT04712643研究中心III期2021-03 启动
  51. Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)状态不明NCT04741165研究中心II期2021-01 启动
  52. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC已完成NCT04948697研究中心II期2021-08 启动
  53. A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab进行中,不再招募NCT04770896研究中心III期2021-04 启动
  54. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev进行中,不再招募NCT04649489研究中心III期2021-04 启动
  55. A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation进行中,不再招募NCT04639180研究中心III期2021-04 启动
  56. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)已终止NCT04246177研究中心III期2020-05 启动
  57. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC已完成NCT04723004研究中心III期2020-10 启动
  58. A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor进行中,不再招募NCT04008797研究中心I/II期2019-07 启动
  59. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation已完成NCT04102098研究中心III期2019-12 启动
  60. Study of BGB-A317 in Participants With Previously Treated Unresectable HCC已完成NCT03419897研究中心II期2018-04 启动
  61. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动
  62. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects已终止NCT03236649研究中心III期2017-09 启动
  63. A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC已完成NCT03516071研究中心II期2017-05 启动
  64. A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma已完成NCT02508467研究中心I期2015-07 启动
  65. Urea Cream Treatment Sorafenib-Associated HSFR in HCC已完成NCT01934829研究中心II期2009-07 启动
  66. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)已完成NCT00617981研究中心III期2008-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 78 篇,占 0.8%。

牵头论文
78
2021–2025 年
牵头试验
36
任何状态,ClinicalTrials.gov
牵头的开放试验
6
正在或即将招募
作为研究中心的开放试验
13
由其他机构牵头
每年牵头的论文数
2021: 151520212022: 8820222023: 202020232024: 141420242025: 19192025

天津有 3 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 19

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    The Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric Cancer
    分期
    未注明
    开始
    2025-08
    登记号
    NCT07183150

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  2. 正在招募
    A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)
    分期
    II期
    开始
    2024-07
    登记号
    NCT06506292

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  3. 正在招募
    Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression
    分期
    II期
    开始
    2024-09
    登记号
    NCT06560528

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  4. 正在招募
    A Phase III Study Comparing Total and Partial Omentectomy for Patients With Advanced Gastric Cancer
    分期
    不分期
    开始
    2021-01
    登记号
    NCT04843215

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  5. 即将招募
    Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer
    分期
    II期
    开始
    2024-06
    登记号
    NCT06454435

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  6. 邀请入组
    Laparoscopic Staging for Stage III Gastric Cancer
    分期
    不分期
    开始
    2025-02
    登记号
    NCT07533825

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  7. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  8. 正在招募
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    分期
    III期
    开始
    2026-12
    登记号
    NCT07789184

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 25 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南昌、大连、天津、广州、杭州、武汉、济南、西安、重庆、长春、青岛

  9. 正在招募
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    分期
    III期
    开始
    2025-02
    登记号
    NCT06731478

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 23 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、厦门、合肥、哈尔滨、天津、太原、常州、徐州、杭州、武汉、沈阳、济南、福州、苏州、西安、郑州、银川

  10. 正在招募
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    分期
    未注明
    开始
    2025-02
    登记号
    NCT06846996

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春

  11. 正在招募
    A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
    分期
    I/II期
    开始
    2025-08
    登记号
    NCT07070232

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心天津、杭州、武汉、重庆

  12. 正在招募
    A Study of LY4257496 in Participants With Cancer (OMNIRAY)
    分期
    I期
    开始
    2025-08
    登记号
    NCT07114601

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心北京、天津

  13. 正在招募
    Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
    分期
    II期
    开始
    2025-12
    登记号
    NCT07127822

    年龄 18 岁 至 未注明(登记的条件)

    牵头:北京大学肿瘤医院;另有 8 家列出的医院为研究中心北京、哈尔滨、天津、太原、成都、石家庄、西安、郑州、青岛

  14. 正在招募
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
    分期
    I/II期
    开始
    2024-06
    登记号
    NCT06324357

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心上海、南京、哈尔滨、天津、杭州、郑州、长春

  15. 正在招募
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    分期
    III期
    开始
    2024-11
    登记号
    NCT06532006

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、常州、广州、徐州、成都、杭州、石家庄、福州、蚌埠、郑州、重庆、银川、长春、长沙、青岛

  16. 正在招募
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    分期
    II期
    开始
    2024-11
    登记号
    NCT06632262

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、厦门、哈尔滨、天津、太原、徐州、成都、杭州、武汉、沈阳、石家庄、襄阳、贵阳、郑州

  17. 正在招募
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    分期
    未注明
    开始
    2023-09
    登记号
    NCT06035250

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南宁、天津、广州、昆明、沈阳、福州、苏州、郑州、长沙、青岛

  18. 正在招募
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    分期
    I/II期
    开始
    2022-01
    登记号
    NCT05150691

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙

  19. 正在招募
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
    分期
    I期
    开始
    2021-06
    登记号
    NCT04900818

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、合肥、哈尔滨、天津、广州、杭州、武汉、沈阳、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期影像与人工智能早期发现与内镜
论文中的科室肿瘤内科病理/检验科消化/肝病科影像/核医学科
牵头的论文78
  1. Neoadjuvant chemotherapy with docetaxel, oxaliplatin, and S-1 versus oxaliplatin and S-1 for locally advanced gastric adenocarcinoma: A multicenter, real-world cohort study.2026International journal of cancer
  2. Elucidating the molecular mechanisms of the mongolian medicine Ana Gaqi Nari in gastric cancer treatment through a multi-omics-guided experimental validation.2026Phytomedicine : international journal of phytotherapy and phytopharmacology
  3. The combination of anti-PD-1 antibodies, trastuzumab and chemotherapy may improve the outcome of some patients with HER2-positive alpha-fetoprotein-producing gastric cancer: a retrospective real-world analysis from a single center.2025BMC cancer免费全文
  4. Construction and validation of a lactylation-based gene signature for prognostic assessment and immune infiltration analysis in gastric adenocarcinoma.2025BMC medical genomics免费全文
  5. Inhibitory effects of circR-127aa on gastric cancer progression and tumor growth.2025Cellular signalling
  6. The clinical significance assessment of the transverse lymph node metastasis in gastric cancer: The establishment and validation of nomogram from a single clinical medical center.2025Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  7. Spectral CT-based nomogram for preoperative prediction of Lauren classification in locally advanced gastric cancer: a prospective study.2025European radiology
  8. Neoadjuvant serplulimab and SOX chemotherapy for locally advanced gastric cancer: pathological responses and systemic immune signatures from a phase II trial.2025Frontiers in immunology免费全文
  9. Functional and clinical validation of tsRNA-defined molecular subtypes guides precision therapy in gastric cancer.2025Frontiers in immunology免费全文
  10. Identification of prognosis and therapy related intratumoral microbiome and immune signatures in gastric cancer.2025Frontiers in immunology免费全文
  11. Multi-omics sequencing of gastroesophageal junction adenocarcinoma reveals prognosis-relevant key factors and a novel immunogenomic classification.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  12. Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer.2025International journal of cancer免费全文
  13. Artificial neural network model enhancing the accuracy of clinical evaluation for high-risk population of lymph node metastasis in non-intestinal type early gastric cancer: a multicenter real-world study in China.2025International journal of surgery (London, England)免费全文
  14. Comparative analysis of engineered-exosome delivered si-HER2 and trastuzumab in the treatment of HER2-positive gastric cancer.2025Investigational new drugs
  15. Evaluation of Raw Cell-Free DNA Sequences for Gastric Cancer Detection.2025JCO precision oncology
  16. Clinicopathological Characteristics and Perioperative Treatment of Epstein-Barr Virus-Associated Gastric Cancer: A Retrospective Study.2025Oncology
  17. Exosomal miR-224-3p promotes lymphangiogenesis and lymph node metastasis by targeting GSK3B in gastric cancer.2025Oncology research免费全文
  18. Pan-cancer landscape of ITGAV and its potential role in gastric cancer.2025Scientific reports免费全文
  19. Risk assessment of lymph node metastasis in early gastric cancer patients with vagus nerve-preserving gastrectomy: A multiple centers potential analysis in China.2025Surgery
  20. Examining more than 35 lymph nodes improves the staging and survival in resectable advanced gastric cancer: a multi-institutional study in China.2025Surgery today
  21. Glycosylation Triggers Cathepsin D Maturation and Secretion to Promote Gastric Cancer Development.2025The American journal of pathology
  22. Comparison of short‑term outcomes and 3-year overall survival between robotic and laparoscopic gastrectomy for gastric cancer: a propensity score matching analysis.2024Acta chirurgica Belgica
  23. ASO Author Reflections: Optimizing Therapy Strategies for Early Gastric Cancer by Leveraging Innovative Predictors of Lymph Node Involvement.2024Annals of surgical oncology
  24. The Key Role of Tumor Budding in Predicting the Status of Lymph Node Involvement in Early Gastric Cancer Patients: A Clinical Multicenter Validation in China.2024Annals of surgical oncology
  25. A Novel lncRNA FUAT1/TNS4 Axis Confers Chemoresistance by Suppressing Reactive Oxygen Species-Mediated Apoptosis in Gastric Cancer.2024Antioxidants & redox signaling
  26. Biomarkers of lipid metabolism in gastric cancer: a case control study.2024BMC cancer免费全文
  27. EGLN3 attenuates gastric cancer cell malignant characteristics by inhibiting JMJD8/NF-κB signalling activation independent of hydroxylase activity.2024British journal of cancer免费全文
  28. From complexity to clarity: development of CHM-FIEFP for predicting effective components in Chinese herbal formulas by using big data.2024Cancer biology & medicine免费全文
  29. Combinational zimberelimab plus lenvatinib and chemotherapy for alpha-fetoprotein elevated, advanced gastric cancer patients (AFPGC): a phase 1 dose-escalation study.2024Cancer immunology, immunotherapy : CII免费全文
  30. ACAT2 suppresses the ubiquitination of YAP1 to enhance the proliferation and metastasis ability of gastric cancer via the upregulation of SETD7.2024Cell death & disease免费全文
  31. DNA methylation-mediated suppression of TUSC1 expression regulates the malignant progression of esophagogastric junction cancer.2024Clinical epigenetics免费全文
  32. Ketohexokinase-A deficiency attenuates the proliferation via reducing β-catenin in gastric cancer cells.2024Experimental cell research
  33. Establishment and validation of a risk score model based on EUS: assessment of lymph node metastasis in early gastric cancer.2024Gastrointestinal endoscopy
  34. Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy.2024Journal for immunotherapy of cancer免费全文
  35. Gastric cancer secreted miR-214-3p inhibits the anti-angiogenesis effect of apatinib by suppressing ferroptosis in vascular endothelial cells.2024Oncology research免费全文
  36. Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial.2023BMC cancer免费全文
  37. Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis.2023BMC cancer免费全文
  38. Cohort profile: design and methods of the Chinese colorectal, breast, lung, liver, and stomach cancer screening trial (C-BLAST).2023Cancer biology & medicine免费全文
  39. Construction and testing of a risk prediction classifier for cardia carcinoma.2023Carcinogenesis
  40. The microprotein encoded by exosomal lncAKR1C2 promotes gastric cancer lymph node metastasis by regulating fatty acid metabolism.2023Cell death & disease免费全文
  41. SMYD3 drives the proliferation in gastric cancer cells via reducing EMP1 expression in an H4K20me3-dependent manner.2023Cell death & disease免费全文
  42. Initial clinical and experimental analyses of ALDOA in gastric cancer, as a novel prognostic biomarker and potential therapeutic target.2023Clinical and experimental medicine
  43. E3 ubiquitin ligase RNF180 prevents excessive PCDH10 methylation to suppress the proliferation and metastasis of gastric cancer cells by promoting ubiquitination of DNMT1.2023Clinical epigenetics免费全文
  44. Inactivation of ZSCAN18 by promoter hypermethylation drives the proliferation via attenuating TP53INP2-mediated autophagy in gastric cancer cells.2023Clinical epigenetics免费全文
  45. DEPTOR as a novel prognostic marker inhibits the proliferation via deactivating mTOR signaling pathway in gastric cancer cells.2023Experimental cell research
  46. Development of a modified ABC method among Helicobacter pylori infected but serum pepsinogen test-negative individuals.2023Helicobacter
  47. Clinicopathological and genetic characteristics of gastric neuroendocrine tumour (NET) G3 and comparisons with neuroendocrine carcinoma and NET G2.2023Histopathology
  48. Exploring the molecular characteristics of the malignant potential of gastric adenocarcinoma with enteroblastic differentiation.2023Histopathology
  49. Efficacy of PD-1/PD-L1 inhibitors in advanced gastroesophageal cancer based on characteristics: a meta-analysis.2023Immunotherapy
  50. Development and validation of prognostic model based on extragastric lymph nodes metastasis and lymph node ratio in node-positive gastric cancer: a retrospective cohort study based on a multicenter database.2023International journal of surgery (London, England)免费全文
  51. Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer.2023Journal of advanced research免费全文
  52. circIPO7 dissociates caprin-1 from ribosomes and inhibits gastric cancer cell proliferation by suppressing EGFR and mTOR.2023Oncogene免费全文
  53. EDIL3 is a potential prognostic biomarker that correlates with immune infiltrates in gastric cancer.2023PeerJ免费全文
  54. Imaging lymph node regression can predict the pathological tumor regression grade in gastric cancer after neoadjuvant treatment.2023Surgery
  55. ALDOC regulated the biological function and immune infiltration of gastric cancer cells.2023The international journal of biochemistry & cell biology
  56. Cancer-suppressing miR-520-3p gene inhibits proliferation, migration, and invasion of gastric cancer cells through targeted regulation of KLF7.2022Bulletin du cancer
  57. Exosomal miR-155 from gastric cancer induces cancer-associated cachexia by suppressing adipogenesis and promoting brown adipose differentiation via C/EPBβ.2022Cancer biology & medicine免费全文
  58. The Number of Positive Tumor Markers (NPTM) Achieves Higher Value in the Prognosis Prediction of Gastric Cancer.2022Disease markers免费全文
  59. The effects of TNF-α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer.2022International journal of cancer免费全文
  60. TAZ promotes vasculogenic mimicry in gastric cancer through the upregulation of TEAD4.2022Journal of gastroenterology and hepatology
  61. Role of non-coding RNA in immune microenvironment and anticancer therapy of gastric cancer.2022Journal of molecular medicine (Berlin, Germany)
  62. Genetic alterations in gastric amphicrine carcinomas and comparison with gastric mixed neuroendocrine-non-neuroendocrine neoplasms.2022Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  63. Risk assessment of lymph node metastasis in early gastric cancer: Establishment and validation of a Seven-point scoring model.2022Surgery
  64. A CT-based Radiomics Model for Prediction of Lymph Node Metastasis in Early Stage Gastric Cancer.2021Academic radiology
  65. Gastric cancer derived exosomes mediate the delivery of circRNA to promote angiogenesis by targeting miR-29a/VEGF axis in endothelial cells.2021Biochemical and biophysical research communications
  66. Prospective study of the effect of ERAS on postoperative recovery and complications in patients with gastric cancer.2021Cancer biology & medicineRCT免费全文
  67. Chemotoxicity-induced exosomal lncFERO regulates ferroptosis and stemness in gastric cancer stem cells.2021Cell death & disease免费全文
  68. circEVI5 acts as a miR-4793-3p sponge to suppress the proliferation of gastric cancer.2021Cell death & disease免费全文
  69. Interrogation of gender disparity uncovers androgen receptor as the transcriptional activator for oncogenic miR-125b in gastric cancer.2021Cell death & disease免费全文
  70. DNMT3A-mediated silence in ADAMTS9 expression is restored by RNF180 to inhibit viability and motility in gastric cancer cells.2021Cell death & disease免费全文
  71. Alterations in mucosa-associated microbiota in the stomach of patients with gastric cancer.2021Cellular oncology (Dordrecht, Netherlands)免费全文
  72. Immune Infiltration Subtypes Characterization and Identification of Prognosis-Related lncRNAs in Adenocarcinoma of the Esophagogastric Junction.2021Frontiers in immunology免费全文
  73. Development of a two-circular RNA panel as potential prognostic biomarker for gastric cancer.2021Journal of translational medicine免费全文
  74. VRK1 promotes proliferation, migration, and invasion of gastric carcinoma cells by activating β-catenin.2021Neoplasma
  75. Well differentiated carcinoma with a poor prognosis: a retrospective analysis of papillary gastric adenocarcinoma.2021Surgery today
  76. Effects of a high body mass index on the short-term outcomes and prognosis after radical gastrectomy.2021Surgery today
  77. Superiority of log odds of positive lymph nodes (LODDS) for prognostic prediction after gastric cancer surgery: a multi-institutional analysis of 7620 patients in China.2021Surgery today
  78. Clinical features & treatment of early-stage gastric mucosa-associated lymphoid tissue lymphoma.2021The Indian journal of medical research免费全文
中文论文(未计入)12
  1. [Cytokeratin (pan)-positive EWSR1/FUS::CREB fusion malignant tumor in abdominopelvic cavity: a clinicopathological and molecular analysis of four cases].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Patterns of lymph node metastasis and prognosis in locally-advanced gastric cancer after neoadjuvant immunotherapy combined with chemotherapy].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Surgical strategies of radical gastrectomy for gastric cancer in the era of immunotherapy].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [A 30-year review of gastric cancer surgery: China has achieved leapfrog leadership].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Quality control of lymph node dissection for locally advanced gastric cancer].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. [Prognostic value of a predictive model comprising preoperative inflammatory response and nutritional indexes in patients with gastric cancer].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. [Differences in clinicopathological features, gene mutations, and prognosis between primary gastric and intestinal gastrointestinal stromal tumors in 1061 patients].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [Clinical controversy and research thoughts on lymphadenectomy of gastric cancer].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  9. [Primary pancreatic adenocarcinoma with enteroblastic differentiation: report of a case].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
  10. [Association of status of mismatch repair protein expression and EB virus infection with clinicopathological parameters in 886 gastric adenocarcinoma patients].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  11. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  12. [Progress in conversion therapy for stage IV gastric cancer].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)73
  1. Laparoscopic Staging for Stage III Gastric Cancer邀请入组NCT07533825牵头方不分期2025-02 启动
  2. The Possible Range of No.4sb Lymph Node Dissection of Locally Advanced Distal Gastric Cancer正在招募NCT07183150牵头方2025-08 启动
  3. A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC)正在招募NCT06506292牵头方II期2024-07 启动
  4. Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression正在招募NCT06560528牵头方II期2024-09 启动
  5. Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer即将招募NCT06454435牵头方II期2024-06 启动
  6. A Phase III Study Comparing Total and Partial Omentectomy for Patients With Advanced Gastric Cancer正在招募NCT04843215牵头方不分期2021-01 启动
  7. A Prospective Clinical Study to Validate a Preoperative Risk Scoring Model for LNM in GC Patients已完成NCT06339307牵头方2024-02 启动
  8. Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer状态不明NCT06102772牵头方2023-11 启动
  9. Fruquintinib Combined With TAS102 for Advanced Gastric Cancer状态不明NCT06102785牵头方2023-11 启动
  10. Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer状态不明NCT05974059牵头方II期2023-08 启动
  11. Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer状态不明NCT05853172牵头方II期2023-03 启动
  12. Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed状态不明NCT06102759牵头方2023-11 启动
  13. Concentrated Complex Plant Dietary Elements for Chemotherapy-Induced Diarrhea已完成NCT07460596牵头方II期2023-01 启动
  14. Minimally Invasive Intrathoracic Esophagogastric Side to Side Anastomosis vs. End to Side Anastomosis状态不明NCT05812495牵头方不分期2023-03 启动
  15. Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer状态不明NCT06496789牵头方II期2023-05 启动
  16. Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients状态不明NCT06383559牵头方II期2023-12 启动
  17. The Possible Range of No.12a Lymph Node Dissection of Locally Advanced Gastric Cancer状态不明NCT06033482牵头方2023-06 启动
  18. A Clinical Prospective Study to Validate a Risk Scoring Model for the HMGC After Curative Surgery已完成NCT06023966牵头方2023-09 启动
  19. Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial状态不明NCT05942573牵头方II期2022-12 启动
  20. A Study on the Impact of Intelligent Nutrition Management on Clinical Outcomes in Chemotherapy Patients With Gastrointestinal Malignancies进行中,不再招募NCT06997302牵头方不分期2022-01 启动
  21. Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer状态不明NCT04982939牵头方II期2021-06 启动
  22. Study on the Peristaltic Direction of GI Anastomosis in Roux-en-Y Reconstruction状态不明NCT04801459牵头方不分期2021-04 启动
  23. Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients状态不明NCT05221775牵头方I期2021-11 启动
  24. Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer已完成NCT04354662牵头方II期2020-05 启动
  25. Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer状态不明NCT05228743牵头方不分期2020-09 启动
  26. Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer状态不明NCT04267549牵头方II期2019-05 启动
  27. Chemotherapy Combined With Apatinib and PD-1 Antibody已完成NCT05025033牵头方II期2019-05 启动
  28. A Trial of Total Versus Partial Omentectomy for Advanced Gastric Cancer in Gastrectomy状态不明NCT04108494牵头方不分期2019-01 启动
  29. The Criteria for Lymph Node Sorting for Pathological Examination in Gastric Cancer状态不明NCT03478449牵头方不分期2018-04 启动
  30. An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric状态不明NCT03285906牵头方II/III期2017-03 启动
  31. A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy状态不明NCT02776527牵头方IV期2016-04 启动
  32. A Trial to Evaluate the Superior Mesenteric Vein (14V) Lymphadenectomy for Distal Advanced Gastric Cancer状态不明NCT02272894牵头方2014-07 启动
  33. Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer状态不明NCT02024438牵头方III期2013-12 启动
  34. Trial of Adjuvant Chemotherapy for High Risk Gastric Cancer Patients状态不明NCT01618474牵头方II期2012-05 启动
  35. Clinical Safety and Preliminary Efficacy of AAV-DC-CTL Treatment in Stage IV Gastric Cancer状态不明NCT01637805牵头方I期2012-05 启动
  36. Digestive Tract Reconstruction After Gastrectomy of Gastric Cancer With Type 2 Diabetes状态不明NCT01637350牵头方2012-08 启动
  37. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy正在招募NCT07789184研究中心III期2026-12 启动
  38. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  39. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer正在招募NCT06731478研究中心III期2025-02 启动
  40. A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors正在招募NCT07070232研究中心I/II期2025-08 启动
  41. Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer正在招募NCT07127822研究中心II期2025-12 启动
  42. A Study of LY4257496 in Participants With Cancer (OMNIRAY)正在招募NCT07114601研究中心I期2025-08 启动
  43. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China正在招募NCT06846996研究中心2025-02 启动
  44. A Phase 2 Clinical Study of ABSK061 and ABSK043正在招募NCT06632262研究中心II期2024-11 启动
  45. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer正在招募NCT06532006研究中心III期2024-11 启动
  46. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread正在招募NCT06324357研究中心I/II期2024-06 启动
  47. AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy正在招募NCT06035250研究中心2023-09 启动
  48. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  49. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors正在招募NCT04900818研究中心I期2021-06 启动
  50. Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction进行中,不再招募NCT06576921研究中心II期2024-11 启动
  51. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma已终止NCT06206278研究中心II期2023-10 启动
  52. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  53. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer已终止NCT05149807研究中心II/III期2022-01 启动
  54. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  55. Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)进行中,不再招募NCT05382364研究中心I期2022-06 启动
  56. Study of ESG401 in Adults With Solid Tumors已完成NCT04892342研究中心I/II期2021-09 启动
  57. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression状态不明NCT04714190研究中心III期2021-03 启动
  58. A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction已完成NCT04661150研究中心II期2021-03 启动
  59. A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)已终止NCT04933227研究中心II期2021-08 启动
  60. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers进行中,不再招募NCT05152147研究中心III期2021-12 启动
  61. IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma已完成NCT05327231研究中心I期2020-07 启动
  62. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  63. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection进行中,不再招募NCT04581473研究中心I/II期2020-10 启动
  64. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis状态不明NCT04440605研究中心2020-07 启动
  65. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer已完成NCT03694522研究中心II期2018-09 启动
  66. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer已完成NCT02898077研究中心III期2017-03 启动
  67. Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor状态不明NCT03399253研究中心II/III期2017-12 启动
  68. Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (SEIPLUS)已完成NCT02745509研究中心不分期2016-03 启动
  69. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  70. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)状态不明NCT02461407研究中心II/III期2015-06 启动
  71. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2状态不明NCT02356276研究中心III期2015-05 启动
  72. Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery状态不明NCT02130752研究中心不分期2014-10 启动
  73. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer已完成NCT02178956研究中心III期2014-10 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

天津有 4 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科普外/肝胆胰外科
牵头的论文1
  1. Yap Expression Is Closely Related to Tumor Angiogenesis and Poor Prognosis in Hepatoblastoma.2022Fetal and pediatric pathology
早期论文(2016–2020 年)1
  1. Adult hepatoblastoma: a review of 47 cases.2018ANZ journal of surgery

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.9%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

天津有 2 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 18 篇,占 0.8%。

牵头论文
18
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 5520222023: 3320232024: 2220242025: 662025

天津有 15 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
    分期
    II期
    开始
    2023-06
    登记号
    NCT05830123

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、天津、广州、杭州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文18
  1. SOCS1 depletion drives osteosarcoma stemness and chemoresistance by suppressing ACTN4 degradation.2026Acta pharmacologica Sinica
  2. CT-assessed pectoralis major muscle measurements as risk factors for low neoadjuvant chemotherapy efficacy in osteosarcoma: a retrospective study.2025BMC medical imaging
  3. METTL3-mediated m6A modification of LINC00520 confers glycolysis and chemoresistance in osteosarcoma via suppressing ubiquitination of ENO1.2025Cancer letters
  4. Assessing the current molecular understanding of therapeutic targets in osteosarcoma.2025Expert opinion on therapeutic targets
  5. Integrated multi-omics reveals GABARAP-mediated mitophagy and pyruvate metabolism as key drivers of osteosarcoma progression.2025Frontiers in immunology
  6. Benchmarking PathCLIP for Pathology Image Analysis.2025Journal of imaging informatics in medicine
  7. CD93 aggravates cell proliferation, angiogenesis and immune escape in osteosarcoma through triggering the PI3K/AKT pathway.2025Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  8. Construction of an oxidative phosphorylation-related gene signature for predicting prognosis and identifying immune infiltration in osteosarcoma.2024Aging
  9. Twenty-year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors.2024International journal of cancer
  10. Incidence, survival, and associated factors estimation in osteosarcoma patients with lung metastasis: a single-center experience of 11 years in Tianjin, China.2023BMC cancer
  11. A1BG-AS1 promotes the biological functions of osteosarcoma cells via regulating the microRNA-148a-3p/USP22 axis and stabilizing the expression of SIRT1 through deubiquitinase function.2023Expert opinion on therapeutic targets
  12. Construction and validation of a novel cuproptosis-mitochondrion prognostic model related with tumor immunity in osteosarcoma.2023PloS one
  13. Nomogram predicting leukopenia in osteosarcoma after high-dose methotrexate chemotherapy.2022Aging
  14. Polygonum cuspidatum inhibits the growth of osteosarcoma cells via impeding Akt/ERK/EGFR signaling pathways.2022Bioengineered
  15. EZH2 promotes the progression of osteosarcoma through the activation of the AKT/GSK3β pathway.2022Clinical and experimental pharmacology & physiology
  16. Identification of B cell marker genes based on single-cell sequencing to establish a prognostic model and identify immune infiltration in osteosarcoma.2022Frontiers in immunology
  17. Risk and Prognostic Factors for Different Organ Metastasis in Primary Osteosarcoma: A Large Population-Based Analysis.2022Orthopaedic surgery
  18. Homogenous and Heterogenous Prognostic Factors for Patients with Bone Sarcoma.2021Orthopaedic surgery
早期论文(2016–2020 年)9
  1. Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.2020Cancer biology & medicine
  2. SIAH1/ZEB1/IL-6 axis is involved in doxorubicin (Dox) resistance of osteosarcoma cells.2019Biological chemistry
  3. Lung metastases at the initial diagnosis of high-grade osteosarcoma: prevalence, risk factors and prognostic factors. A large population-based cohort study.2019Sao Paulo medical journal = Revista paulista de medicina
  4. Outcomes of surgery and/or combination chemotherapy for extraskeletal osteosarcoma: a single-center retrospective study from China.2019Scientific reports
  5. ONZIN Upregulation by Mutant p53 Contributes to Osteosarcoma Metastasis Through the CXCL5-MAPK Signaling Pathway.2018Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  6. Overexpression of SENP1 reduces the stemness capacity of osteosarcoma stem cells and increases their sensitivity to HSVtk/GCV.2018International journal of oncology
  7. Downregulation of lncRNA H19 inhibits migration and invasion of human osteosarcoma through the NF-κB pathway.2018Molecular medicine reports
  8. Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV.2017Oncotarget
  9. Coexpression of CXCR4 and MMP9 predicts lung metastasis and poor prognosis in resected osteosarcoma.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas正在招募NCT05830123研究中心II期2023-06 启动
  2. TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors已终止NCT06438783研究中心I期2024-02 启动
  3. IBI188 Combination Therapy in Solid Tumors已终止NCT04861948研究中心I期2021-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

天津有 6 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 21 篇,占 1.9%。

牵头论文
21
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 7720222023: 6620232024: 3320242025: 332025

天津有 11 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
    分期
    II期
    开始
    2026-01
    登记号
    NCT07318831

    年龄 0 岁 至 18 岁(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  2. 正在招募
    APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
    分期
    I/II期
    开始
    2023-02
    登记号
    NCT05701306

    年龄 5 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心天津、广州、武汉

  3. 正在招募
    TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma
    分期
    I期
    开始
    2022-12
    登记号
    NCT05562024

    年龄 1 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心天津、济南

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科病理/检验科普外/肝胆胰外科

这些论文过半是实验室或动物研究。

牵头的论文21
  1. Single-Cell Profiling of the Microenvironment in High-Risk Neuroblastoma.2025IUBMB life
  2. Autophagy inhibition amplifies anti-tumor immunity effect of dinutuximab beta on neuroblastoma via the VEGFR/AKT/mTOR and ROS/NF-κB pathways.2025International immunopharmacology
  3. PLK4 as a Key Regulator of Neuroblastoma Differentiation and a Promising Therapeutic Target.2025International journal of biological sciences
  4. Event-free survival in neuroblastoma with MYCN amplification and deletion of 1p or 11q may be associated with altered immune status.2024BMC cancer
  5. A mitochondria-related genes associated neuroblastoma signature - based on bulk and single-cell transcriptome sequencing data analysis, and experimental validation.2024Frontiers in immunology
  6. Prognostic significance of migrasomes in neuroblastoma through machine learning and multi-omics.2024Scientific reports
  7. Functionalized GD2 Electrochemical Immunosensor to Diagnose Minimum Residual Disease of Bone Marrow in Neuroblastoma Effectively.2023Biosensors
  8. Integrating Bulk-seq and Single-cell-seq Reveals Estrogen and MAPK Pathways Associating with Neuroblastoma Outcome.2023Cancer control : journal of the Moffitt Cancer Center
  9. Optimal combination of MYCN differential gene and cellular senescence gene predicts adverse outcomes in patients with neuroblastoma.2023Frontiers in immunology
  10. Identification of NCAPG as an Essential Gene for Neuroblastoma Employing CRISPR-Cas9 Screening Database and Experimental Verification.2023International journal of molecular sciences
  11. N6-methyladenosine-mediated overexpression of long noncoding RNA ADAMTS9-AS2 triggers neuroblastoma differentiation via regulating LIN28B/let-7/MYCN signaling.2023JCI insight
  12. Integrating bulk-seq and single-cell-seq reveals disulfidptosis potential index associating with neuroblastoma prognosis and immune infiltration.2023Journal of cancer research and clinical oncology
  13. Anlotinib Induces a T Cell-Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma.2022Clinical cancer research : an official journal of the American Association for Cancer Research
  14. A novel ganglioside-related risk signature can reveal the distinct immune landscape of neuroblastoma and predict the immunotherapeutic response.2022Frontiers in immunology
  15. Using a Gene Network of Pyroptosis to Quantify the Responses to Immunotherapy and Prognosis for Neuroblastoma Patients.2022Frontiers in immunology
  16. Analysis of the efficacy of autologous peripheral blood stem cell transplantation in high-risk neuroblastoma.2022International journal of medical sciences
  17. B3GALT4 remodels the tumor microenvironment through GD2-mediated lipid raft formation and the c-met/AKT/mTOR/IRF-1 axis in neuroblastoma.2022Journal of experimental & clinical cancer research : CR
  18. Salsolinol Induces Parkinson's Disease Through Activating NLRP3-Dependent Pyroptosis and the Neuroprotective Effect of Acteoside.2022Neurotoxicity research
  19. The application and value of radiotherapy at the primary site in patients with high-risk neuroblastoma.2022The British journal of radiology
  20. Value of pretreatment 18F-FDG PET/CT in prognosis and the reflection of tumor burden: a study in pediatric patients with newly diagnosed neuroblastoma.2021International journal of medical sciences
  21. Early Decline of Neuron-Specific Enolase during Neuroblastoma Chemotherapy is a Predictive Factor of Clinical Outcome.2021Pediatric hematology and oncology
早期论文(2016–2020 年)6
  1. Polo-like kinase 4 mediates epithelial-mesenchymal transition in neuroblastoma via PI3K/Akt signaling pathway.2018Cell death & disease
  2. TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma.2018Journal of pediatric hematology/oncology
  3. Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.2017Oncotarget
  4. A single center clinical analysis of children with high-risk neuroblastoma.2017Oncotarget
  5. Research progress of neuroblastoma related gene variations.2017Oncotarget
  6. Ultrasound-guided core needle biopsy in the diagnosis of neuroblastic tumors in children: a retrospective study on 83 cases.2017Pediatric surgery international
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children正在招募NCT07318831牵头方II期2026-01 启动
  2. APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors正在招募NCT05701306研究中心I/II期2023-02 启动
  3. TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma正在招募NCT05562024研究中心I期2022-12 启动
  4. Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma已完成NCT05373901研究中心I期2022-06 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

天津有 3 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
牵头的论文1
  1. Twenty-year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors.2024International journal of cancer
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma已完成NCT05046314研究中心II期2024-03 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 10 篇,占 0.6%。

牵头论文
10
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 4420222023: 1120232024: 1120242025: 112025

天津有 5 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 6

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
    分期
    I期
    开始
    2025-08
    登记号
    NCT07114432

    年龄 18 岁 至 未注明(登记的条件)

    牵头:天津医科大学肿瘤医院天津

  2. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  3. 正在招募
    A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
    分期
    III期
    开始
    2026-05
    登记号
    NCT07518186

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心北京、南京、南昌、天津、成都、杭州、武汉、深圳、温州、西安、长春

  4. 正在招募
    A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
    分期
    III期
    开始
    2024-06
    登记号
    NCT06508983

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、天津、广州、杭州、武汉、苏州、西安、郑州

  5. 正在招募
    Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
    分期
    II期
    开始
    2022-04
    登记号
    NCT05294055

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 6 家列出的医院为研究中心北京、合肥、天津、济南、郑州

  6. 正在招募
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    分期
    III期
    开始
    2022-10
    登记号
    NCT05552222

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题联合用药复发与耐药诊断、微小残留病与危险分层

这些论文过半是实验室或动物研究。

牵头的论文10
  1. Serum heat shock protein family A member 9 protein as a biomarker for bortezomib resistance and poor prognosis in patients with multiple myeloma.2026Anti-cancer drugs免费全文
  2. HRP2 regulating MICU1-mediated Ca2+ overload to dictate chemoresistance of multiple myeloma.2025Neoplasia (New York, N.Y.)免费全文
  3. Tandem autologous hematopoietic stem cell transplantation for patients with multiple myeloma: a systematic review and meta-analysis.2024Hematology (Amsterdam, Netherlands)
  4. Influence of diabetes mellitus on the biochemical parameters and outcomes of multiple myeloma.2023Hematology (Amsterdam, Netherlands)
  5. DUT enhances drug resistance to proteasome inhibitors via promoting mitochondrial function in multiple myeloma.2022Carcinogenesis
  6. Posttranslational modification of Aurora A-NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma.2022Clinical and translational medicine免费全文
  7. Hypoxia induces chemoresistance to proteasome inhibitors through orchestrating deSUMOylation and ubiquitination of SRC-3 in multiple myeloma.2022Oncogene
  8. Epigenomic reprogramming via HRP2-MINA dictates response to proteasome inhibitors in multiple myeloma with t(4;14) translocation.2022The Journal of clinical investigation免费全文
  9. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.2021Nature communications免费全文
  10. Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple myeloma.2021Oncogene免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)23
  1. RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma即将招募NCT07114432牵头方I期2025-08 启动
  2. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma正在招募NCT07518186研究中心III期2026-05 启动
  3. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  4. A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients正在招募NCT06508983研究中心III期2024-06 启动
  5. Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma正在招募NCT05294055研究中心II期2022-04 启动
  6. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma正在招募NCT05552222研究中心III期2022-10 启动
  7. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide进行中,不再招募NCT06208150研究中心III期2024-01 启动
  8. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05572515研究中心III期2023-03 启动
  9. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment进行中,不再招募NCT05455320研究中心III期2022-10 启动
  10. A Study of Daratumumab进行中,不再招募NCT05438043研究中心III期2022-12 启动
  11. A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma状态不明NCT05236621研究中心III期2021-01 启动
  12. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)已完成NCT04939142研究中心III期2021-07 启动
  13. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05083169研究中心III期2021-10 启动
  14. A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT04557098研究中心II期2020-09 启动
  15. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03860038研究中心II期2019-01 启动
  16. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03952091研究中心III期2019-03 启动
  17. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.进行中,不再招募NCT03539744研究中心III期2018-10 启动
  18. A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma已终止NCT03215030研究中心I/II期2017-10 启动
  19. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动
  20. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已完成NCT03234972研究中心III期2017-11 启动
  21. Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy已完成NCT02609828研究中心III期2015-10 启动
  22. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma已完成NCT01818752研究中心III期2013-07 启动
  23. A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers已完成NCT01524978研究中心II期2012-04 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

天津有 2 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他相关研究

联系这家医院

出示给工作人员或司机的院名卡

天津医科大学肿瘤医院

Tianjin Medical University Cancer Institute & Hospital

天津

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Tianjin Medical University Cancer Institute and Hospital; Tianjin Medical University Cancer Hospital; Tianjin Cancer Institute; Tianjin Cancer Hospital Airport Hospital; Tianjin Cancer Hospital; Tianjin Medical University Cancer Hospital and Institute; Tianjin Cancer Institute & Hospital; Tianjin Cancer Hospital Airport Branch

提出更正下载数据